Skip to content

Tolerability and efficacy due to the sequence of spraying iodine solution during esophageal chromoendoscopy: a single-blind randomized controlled trial

Comparative tolerability and efficacy between sequential and inverse spraying of iodine solution during esophageal chromoendoscopy: a single-blind randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048789
Enrollment
Unknown
Registered
2021-07-16
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal carcinoma

Interventions

Test group:sequential spraying
control group:inverse spraying

Sponsors

Expert committee of early diagnosis and treatment project for cancer (rural)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients undergoing gastroscopy under intravenous anesthesia, regardless of gender; 2. Patients voluntarily joined the study and gave informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. There are other serious diseases that affect the accuracy of the research, such as severe hepatitis; 3. Patients receiving radiotherapy and chemotherapy; 4. Patients with high risk of bleeding, perforation, obstruction and cancer-related adverse events; 5. Received chromoendoscopy based on iodine staining within one year; 6. Patients with abnormal expression function or unable to cooperate with the completion of the test; 7. Patients with gastroesophageal reflux and other diseases; 8. Patients with contraindications to biopsy; 9. Those who are allergic to iodine solution or iodine components.

Design outcomes

Primary

MeasureTime frame
effects of iodine staining;iodine consumption;

Secondary

MeasureTime frame
pain;oral residual iodine;

Countries

China

Contacts

Public ContactChen Weiqing

Chongqing University Cancer Hospital

CQCH_ChenWQ@163.com+86 18222275023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026